Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer

EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients harboring EGFR activating mutations. However, inhibition response is easily attenuated by drug resistance, which is mainly due to bypass activation or downstream activation. Herein, we established osimertinib-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xueli, Wang, Rui, Gu, Tingxuan, Ma, Fayang, Laster, Kyle Vaughn, Li, Xiang, Liu, Kangdong, Lee, Mee-Hyun, Dong, Zigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535870/
https://www.ncbi.nlm.nih.gov/pubmed/36203195
http://dx.doi.org/10.1186/s12943-022-01662-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535870/
https://www.ncbi.nlm.nih.gov/pubmed/36203195
http://dx.doi.org/10.1186/s12943-022-01662-1

Ejemplares similares